Biocon drops after USFDA delays decision on biosimilar – Business Standard


Biocon drops after USFDA delays decision on biosimilar
Business Standard
Biocon announced after market hours yesterday, 30 August 2017, that the US Food and Drug Administration (USFDA) has delayed by three months its decision on whether it will approve Biocon and Mylan's breast cancer biosimilar drug while it reviews ...

Biocon drops after USFDA delays decision on biosimilar – Business Standard Kitimi Business.